Boston Partners Raises Holdings in Kenvue Inc. (NYSE:KVUE)

Boston Partners grew its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 36.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,595,963 shares of the company's stock after acquiring an additional 6,366,097 shares during the period. Boston Partners owned about 1.23% of Kenvue worth $503,145,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of KVUE. Huntington National Bank grew its stake in shares of Kenvue by 26.5% during the third quarter. Huntington National Bank now owns 4,161 shares of the company's stock worth $96,000 after purchasing an additional 871 shares in the last quarter. Handelsbanken Fonder AB increased its holdings in Kenvue by 2.9% in the fourth quarter. Handelsbanken Fonder AB now owns 742,184 shares of the company's stock valued at $15,846,000 after buying an additional 21,222 shares during the last quarter. Alberta Investment Management Corp increased its holdings in Kenvue by 23.2% in the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company's stock valued at $12,445,000 after buying an additional 109,700 shares during the last quarter. Longbow Finance SA increased its holdings in Kenvue by 5.0% in the fourth quarter. Longbow Finance SA now owns 280,568 shares of the company's stock valued at $5,990,000 after buying an additional 13,287 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC increased its holdings in Kenvue by 143.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 47,938 shares of the company's stock valued at $1,023,000 after buying an additional 28,216 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Remove Ads

Kenvue Price Performance

Kenvue stock traded down $0.05 during mid-day trading on Friday, reaching $23.34. The company had a trading volume of 35,334,673 shares, compared to its average volume of 16,146,816. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market capitalization of $44.61 billion, a P/E ratio of 44.04, a P/E/G ratio of 2.62 and a beta of 1.25. The stock's 50-day simple moving average is $22.08 and its 200-day simple moving average is $22.43.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.51%. Kenvue's dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

KVUE has been the topic of several recent analyst reports. UBS Group dropped their target price on Kenvue from $23.00 to $21.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Citigroup dropped their target price on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a report on Wednesday, January 15th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a "buy" rating to a "hold" rating and dropped their target price for the company from $25.00 to $24.00 in a report on Thursday, December 12th. Barclays decreased their price objective on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating for the company in a research note on Friday, January 17th. Finally, Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $23.75.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.